Immunotherapy has proven to be effective in many types of tumors, especially those with a poor prognosis.
However, immunotherapies against bladder cancer remain limited. Using the biomarkers module of Integrity,
a Cortellis solution,™ we identified potential targets in silico for developing immunotherapies against advanced or metastatic bladder cancer. In particular, we identified an immune checkpoint, PD-L1, a promising class of immunotherapy target.
Complete the form opposite to get the full report.